Abstract

Hawkins, Inc. will report its fiscal fourth-quarter and full-year results on May 13, 2026 Post Market; this preview summarizes the latest quarter’s performance, consensus expectations for revenue, profitability and EPS, and the key themes investors are watching into the print.

Market Forecast

Consensus for the fiscal fourth quarter points to revenue of 255.28 million US dollars, up 10.66% year over year, EBIT of 24.21 million US dollars, up 3.79% year over year, and EPS of 0.76, up 3.99% year over year. Margin forecasts are not formally outlined, though investors are focused on gross profit discipline and earnings quality; adjusted EPS is expected to grow modestly in line with the revenue mix shift. The main business is expected to remain driven by the company’s water-treatment offerings, with a stable margin profile and operating leverage from cost control and mix. The most promising near-term segment is expected to be Health and Nutrition, which delivered approximately 63.46 million US dollars last quarter based on mix, with year-over-year segment growth not disclosed; execution on mix and pricing remains the primary watch item.

Last Quarter Review

In the previous quarter, Hawkins, Inc. reported revenue of 244.08 million US dollars, a gross profit margin of 20.82%, GAAP net profit attributable to shareholders of 14.31 million US dollars, a net profit margin of 5.86%, and adjusted EPS of 0.69, representing a year-over-year change of 7.90% for revenue and -4.17% for EPS. A key financial takeaway was that revenue growth outpaced EPS, highlighting the importance of gross margin discipline and operating cost normalization into fiscal year-end. From a business-mix perspective, Water Treatment remained the largest contributor at an estimated 131.35 million US dollars based on mix, followed by Health and Nutrition at 63.46 million US dollars and Industrial at 49.27 million US dollars; segment-level year-over-year growth was not disclosed.

Current Quarter Outlook (with major analytical insights)

Main business: Water Treatment execution and gross margin discipline

Water Treatment continues to anchor revenue and profit, and investors will focus on the interplay between volumes, pricing, and product mix as the principal drivers of gross margin. Consensus implies mid–single-digit EBIT growth and modest EPS growth, which places a premium on maintaining the 20%+ gross margin cadence seen last quarter. The mix within Water Treatment can move margins by several tens of basis points, so even small shifts in higher-value chemistries, services, or logistics surcharges could be material to the quarter’s operating leverage. Seasonality and procurement timing are also important. The fourth fiscal quarter typically captures late-winter to early-spring demand patterns; inventory positioning and freight costs can amplify or mute gross margin realization. With last quarter’s gross margin at 20.82%, holding price relative to cost inputs is likely the single largest factor for earnings stability this quarter. A flat-to-modestly higher gross margin combined with revenue growth of 10.66% year over year would be sufficient to advance EPS in line with the 3.99% implied by consensus. Cash conversion and working-capital churn are secondary but notable considerations, particularly given the scale of Water Treatment sales. A disciplined approach to receivables and inventories can free cash to support targeted capital and tuck-in activity as the company moves into the next fiscal period. Investors are likely to look for indications that procurement costs have stabilized and that the company is managing logistics efficiently, which would support consistent flow-through from revenue to EBIT.

Most promising business: Health and Nutrition mix-led upside

Health and Nutrition remains a candidate for outperformance in the near term given its revenue base and the ability to drive incremental margin through product mix and disciplined pricing. Last quarter, the segment accounted for approximately 63.46 million US dollars based on revenue mix. While the tool data does not provide segment-level year-over-year growth rates, the overall company revenue trajectory of 7.90% in the prior quarter and 10.66% expected for the current quarter suggests that Health and Nutrition can contribute meaningfully to aggregate growth if mix shifts favor higher-value offerings. The profit profile of Health and Nutrition tends to be sensitive to the ratio of specialty ingredients versus more commoditized inputs. A higher specialty mix generally supports better gross margins, which, coupled with consistent operating expense control, can translate into outsized contribution to EPS relative to revenue. In the context of the current quarter’s consensus—EPS up 3.99% year over year against revenue up 10.66%—this implies that margin management within Health and Nutrition will be a focal point for investors assessing earnings quality. Execution will also hinge on supply-chain reliability, lead-time management, and the ability to pass through cost changes where appropriate. The company’s recent communication cadence and operating performance point to steady operational execution. If Health and Nutrition demonstrates pricing resilience and product-mix expansion, it can help offset any variability that arises in other segments and provide support to the consolidated EBIT outlook of 24.21 million US dollars.

Stock price drivers this quarter: revenue mix, gross margin trajectory, and forward color

The main stock-price lever into the print is whether revenue growth converts to EPS in line with the forecasted trajectory. With consensus looking for 255.28 million US dollars in revenue, a key test will be if gross margins hold near or above the 20% threshold observed in the prior quarter. A 50–100 basis-point variance in gross margin can produce a noticeable delta in quarterly EBIT, given the scale of revenue, which in turn affects EPS relative to the 0.76 consensus. A second driver is management’s commentary on early-fiscal trends and the integration path for the recently closed Aqua-Chem asset acquisition on April 30, 2026. Although the timing falls after the fiscal quarter being reported, investors will seek clarity on how these assets will be integrated, the expected contribution timing, and any incremental capital or operating cost needs. Clear direction on synergy capture and customer coverage expansion would help frame expectations for the first quarter of the next fiscal year and beyond. Finally, capital allocation and operating expense discipline will shape sentiment. Investors will weigh the sustainability of cost controls that supported EBIT in the prior quarter against any necessary investments to support growth. If operating expenses remain well managed while revenue scales, the company can potentially deliver above-plan EPS even without significant margin expansion. Conversely, any indication of margin compression or higher-than-expected operating costs could cap upside to consensus EPS of 0.76. Management’s guidance tone on revenue cadence and margin guardrails will therefore be pivotal to how shares react post release.

Analyst Opinions

Across the period from January 1, 2026 to May 6, 2026, publicly available institutional commentary specific to Hawkins’s upcoming quarter has been limited. The balance of published references trends constructive, with no identifiable bearish previews in the window reviewed. Based on the collected items, the ratio of bullish to bearish commentary stands at approximately 100% to 0%. Institutional engagement and corporate actions are framing that constructive tone. The company’s April 29, 2026 notice of the upcoming May 13 report set expectations for a straightforward fiscal fourth quarter update. In parallel, the April 30, 2026 announcement that Hawkins acquired the assets of Aqua-Chem, Inc. in Nebraska and Iowa was taken as a positive indicator of ongoing strategic expansion and disciplined capital deployment. While these communications are not themselves analyst ratings, they shape institutional narratives heading into the print by signaling growth-oriented activity and a clear operating agenda. We also note Hawkins’s participation announcement on February 18, 2026 for a prominent institutional investor conference during the quarter, which keeps the company in front of buy-side and sell-side audiences ahead of results. Such engagement often supports visibility around forward expectations and provides a venue for management to elaborate on mix, costs, and capital priorities. In the absence of explicit target or rating changes during the period, the consensus embedded in the numbers—revenue up 10.66% year over year, EBIT up 3.79%, and EPS up 3.99%—serves as the de facto market view and is consistent with the constructive tone of institutional interactions. Putting these elements together, the majority view is that Hawkins enters the quarter with a credible path to a modest year-over-year improvement in revenue and EPS, underpinned by mix and cost discipline. The key debate articulated in market conversations centers on margin sustainability: whether gross margin can remain near the prior quarter’s 20.82% while revenue scales to 255.28 million US dollars. On balance, the outlook embedded in current expectations and in recent institutional touchpoints leans constructive, with the forthcoming commentary on early fiscal trends and post-close integration of the acquired Aqua-Chem assets likely to be the swing factors for how investors recalibrate models after May 13, 2026.